ZBH

Rating neutralAI MemoPost-earnings T+3

Zimmer Biomet

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and raised outlook • 2026-08-05

Base target: $106 / p=50% prob

Biggest risk

Adjusted EPS was flat year over year, total knee growth was only 0.1% organically with international knees down 1.5%, and the commercial transformation remains execution-sensitive. No reliable post-print analyst estimate revisions, rating changes, or target changes were identified, limiting confirmation of the bullish interpretation.

Invalidation

Break below $85 or thesis failure.

What would change my mind?

Q2 delivered 4.0% organic constant-currency growth, strong S.E.T. and technology/data/surgical momentum, solid free cash flow, and a raised 2026 outlook. Successful sales-force transformation and continued robotics and product adoption could support durable mid-single-digit growth [#SEC-8K-2026-08-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$106

p=50%

Bull target

$118

p=25%

Bear target

$85

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion after guidance raise
ROSA Shoulder launch and innovation-cycle conversion
Commercial transformation and procedure-volume execution

BearKey bullets

Adjusted EPS was flat year over year despite revenue growth, leaving margin and cost execution important.
Execution risk in the U.S.
sales-force and go-to-market transformation.

WatchKey bullets

Q2 2026 results and raised outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $106 (p=50%)

Target spread vs base: +12% / -20%

Scenario probabilities

Bull Target: $118 (p=25%)Base Target: $106 (p=50%)Bear Target: $85 (p=25%)

Commentary

The company source is concrete and recent: the Aug. 5 Form 8-K earnings exhibit reports the Q2 results, guidance increase, operating drivers, and product milestones [#SEC-8K-2026-08-05]. News tone is constructive, but the Aug. 7 market snapshot showed a roughly 0.7% decline from the prior close, and no reliable post-print analyst revision or target-change evidence was identified. Social and options evidence are unavailable; this remains a cautious T+3 monitoring view rather than a strong directional signal.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion after guidance raise
ROSA Shoulder launch and innovation-cycle conversion
Commercial transformation and procedure-volume execution

Scenarios

Bull Target (Scenario probability)

$118 / p=25% prob

Base Target (Scenario probability)

$106 / p=50% prob

Bear Target (Scenario probability)

$85 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-08-05
Q2 2026 results and raised outlook
Zimmer Biomet’s Exhibit 99.1 earnings release filed with its Aug. 5 Form 8-K reported Q2 sales of $2.177 billion, 4.0% organic constant-currency growth, adjusted EPS of $2.07, and $308.3 million of free cash flow. Full-year organic constant-currency revenue guidance increased to 2.25%-3.25% and adjusted EPS guidance to $8.47-$8.59 [#SEC-8K-2026-08-05].
Prob 95.00% • Move 5.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion after guidance raise
2026-08-15
The company’s Q2 release and raised full-year outlook were constructive, but a market snapshot showed ZBH at $96.55 on Aug. 7, down 0.68%, versus the Aug. 6 RankAlpha anchor of $97.19. No reliable post-print analyst revision or target change was identified, so near-term trading may remain range-bound [#SEC-8K-2026-08-05].
Prob 70% • Move 3% • Priced-in 70%

Long-term Catalysts

Months to a year

ROSA Shoulder launch and innovation-cycle conversion
2026-12-31
The company received FDA 510(k) clearance and completed first cases for the next-generation ROSA Shoulder System, while technology, data and surgical sales grew 21.5% organically in Q2. Sustained adoption and conversion of the innovation cycle into durable growth remain a medium-term upside test [#SEC-8K-2026-08-05].
Prob 65% • Move 8% • Priced-in 50%
Commercial transformation and procedure-volume execution
2026-12-31
Management said go-to-market changes were progressing as planned, but the thesis still depends on execution by the predominantly direct and specialized sales model and on improvement in procedure categories beyond stronger hips and S.E.T. performance. Evidence through the second half of 2026 is the key validation point [#SEC-8K-2026-08-05].
Prob 60% • Move 9% • Priced-in 45%

Risks

Adjusted EPS was flat year over year despite revenue growth, leaving margin and cost execution important.
Execution risk in the U.S. sales-force and go-to-market transformation.
No reliable post-print analyst revisions, consensus surprise comparison, or target-change evidence was identified.
Product launches and robotics investments may not convert into sustained adoption or share gains.
Weakness in knee procedures, particularly internationally, could offset stronger hips and S.E.T. categories.

Peers

Symbol	Summary
EW	Edwards Lifesciences is a higher-growth medtech comparator with stronger procedure and technology momentum; ZBH likely needs cleaner robotics and sales-execution evidence to justify a similar premium multiple.
BSX	Boston Scientific remains a faster-growth diversified device company, highlighting that ZBH currently looks more like a steadier cash-flow story than a premium-growth medtech name.
COO	Cooper is closer on size but has a different business mix, making it only a loose valuation check; peer read-through should therefore be treated cautiously.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

Edwards Lifesciences is a higher-growth medtech comparator with stronger procedure and technology momentum; ZBH likely needs cleaner robotics and sales-execution evidence to justify a similar premium multiple.

BSX

Boston Scientific remains a faster-growth diversified device company, highlighting that ZBH currently looks more like a steadier cash-flow story than a premium-growth medtech name.

COO

Cooper is closer on size but has a different business mix, making it only a loose valuation check; peer read-through should therefore be treated cautiously.